TrialThe Journal of allergy and clinical immunology2020
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Yang Cao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
281 papers cite itlatest 60 shown
this paperpooled ittrialcites it